Circulating neprilysin clears brain amyloid.
The use of the peptidase neprilysin (NEP) as a therapeutic for lowering brain amyloid burden is receiving increasing attention. We have previously demonstrated that peripheral expression of NEP on the surface of hindlimb muscle lowers brain amyloid burden in a transgenic mouse model of Alzheimer's disease. In this study we now show that using adeno-associated virus expressing a soluble secreted form of NEP (secNEP-AAV8), NEP secreted into plasma is effective in clearing brain Abeta. Soluble NEP expression in plasma was sustained over the 3-month time period it was measured. Secreted NEP decreased plasma Abeta by 30%, soluble brain Abeta by approximately 28%, insoluble brain Abeta by approximately 55%, and Abeta oligomersby 12%. This secNEP did not change plasma levels of substance P or bradykinin, nor did it alter blood pressure. No NEP was detected in CSF, nor did the AAV virus produce brain expression of NEP. Thus the lowering of brain Abeta was due to plasma NEP which altered blood-brain Abeta transport dynamics. Expressing NEP in plasma provides a convenient way to monitor enzyme activity during the course of its therapeutic testing.
Liu
Yinxing
Y
Department of Molecular and Cellular Biochemistry, University of Kentucky, College of Medicine, Lexington, KY 40536-0509, USA.
Studzinski
Christa
C
Beckett
Tina
T
Murphy
M Paul
MP
Klein
Ronald L
RL
Hersh
Louis B
LB
D016229:Amyloid beta-Peptides / Q000378:metabolism*; D000818:Animals; D001794:Blood Pressure; D001812:Blood-Brain Barrier / Q000201:enzymology; D001920:Bradykinin / Q000097:blood; D001921:Brain / Q000378:metabolism*; D001923:Brain Chemistry; D000229:Dependovirus; D006801:Humans; D051379:Mice; D015260:Neprilysin / Q000097:blood* / Q000235:genetics; D013373:Substance P / Q000097:blood
D016229:Amyloid beta-Peptides; D013373:Substance P; D015260:Neprilysin; D001920:Bradykinin